• CroíValve announces successful first human use of its Duo Tricuspid Coaptation Valve technology

    March 23, 2020

    Dublin, Ireland, 23 March 2020 - CroíValve announced today the successful first human use of its Duo Tricuspid Coaptation Valve technology for tricuspid repair. The procedure was performed by an experienced Heart Team in St. James University Hospital Dublin, led by Dr. Stephen O’Connor, MD, Interventional Cardiologist and Mr. Michael Tolan, MD, CardiacSurgeon, assisted by Dr. Andrew Maree, Dr. Charlie McCreery and Dr. Caroline Daly. Read full press release here.

    Read More
  • Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board

    February 24, 2020

    Philadelphia, PA, February 24, 2020 – Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board of directors and scientific advisory board. Read full press release here.

    Read More
  • Aria CV Receives FDA Breakthrough Designation for Its Medical Device for Treating Pulmonary Arterial Hypertension

    February 6, 2020

    February 06, 2020 07:00 AM Eastern Standard Time SAINT PAUL, Minn.--(BUSINESS WIRE)--Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria CV Pulmonary Hypertension System (Aria CV PH System). The Breakthrough Devices Program (BDP) is intended to expedite the FDA review and approval of designated devices that may provide more effective treatment of life-threatening or irreversibly debilitating diseases. BDP is intended to help

    Read More